HomeBUSINESS
BUSINESS

Astellas’ Half-Year Operating Profit Down 38.8% on LLP Divestiture, Micardis Gx Erosion
(Nov.1.2017)

Astellas Pharma saw its group operating profit slide 38.8% in April-September as it offloaded its global dermatology franchise and older established assets, while facing generic competition for its heavyweight hypertension med Micardis (telmisartan) ...
(LOG IN FOR FULL STORY)